Basic Information
LncRNA/CircRNA Name | LINC00152 |
Synonyms | CYTOR, C2orf59, LINC00152, NCRNA00152 |
Region | GRCh38_2:87454781-87636740 |
Ensemble | ENSG00000222041 |
Refseq | NR_024204 |
Classification Information
Regulatory Mechanism | Biological Function | Clinical Application | |||
---|---|---|---|---|---|
TF | Immune | Survival | |||
Enhancer | Apoptosis | Drug | |||
Variant | Cell Growth | Circulating | |||
MiRNA | EMT | Metastasis | |||
Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
Cancer Name | colon cancer |
ICD-0-3 | C18 |
Methods | qPCR, Western blot, Luciferase reporter assay, Cell proliferation assay etc. |
Sample | colon cancer tissues, cell lines (SW480, Caco2, SW620 and HT29) |
Expression Pattern | up-regulated |
Function Description | Elevated expression of Linc00152 was observed by using qRT-PCR in colon cancer tissues when compared with adjacent normal mucosa. Linc00152 as a candidate prognostic indicator of outcome and drug responsiveness in colon cancer patients, and the involvement of competing endogenous RNAs mechanism in Linc00152/miR-193a-3p/ERBB4/AKT signaling axis may provide a novel choice in the investigation of drug resistance. |
Pubmed ID | 27633443 |
Year | 2016 |
Title | Linc00152 Functions as a Competing Endogenous RNA to Confer Oxaliplatin Resistance and Holds Prognostic Values in Colon Cancer. |
External Links
Links for LINC00152 | GenBank HGNC NONCODE |
Links for colon cancer | OMIM COSMIC |